Niki BioSolutions awards Sheinerman 8,000 options

The award’s vesting schedule ties 2,000 options to merger closing and the remaining options to quarterly installments after the merger’s effective date.

Rhea-AI Filing Summary

Niki BioSolutions, Inc. director and 10% owner Kira Sheinerman received an award of 8,000 stock options on July 22, 2026, exercisable at $8.83 per share and expiring July 22, 2036. The options cover 8,000 common shares. Under the award terms, 2,000 options vested immediately upon the merger closing; the remaining 6,000 vest in three equal quarterly installments of 2,000, beginning on the first business day of the first full quarter following the merger’s effective date.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Sheinerman Kira

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	8,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 8,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest as follows: (i) 2,000 options vested immediately upon the closing of the merger; and (ii) the remaining 6,000 options vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.

Key Figures

Options awarded: 8,000 options Exercise price: $8.83 per share Common shares underlying options: 8,000 shares +3 more

6 metrics

Options awarded 8,000 options Award to Kira Sheinerman on July 22, 2026

Exercise price $8.83 per share Price to exercise the options

Common shares underlying options 8,000 shares Shares covered by the options

Expiration date July 22, 2036 Option expiration

Options vested at merger closing 2,000 options Vested immediately upon closing of the merger

Options in quarterly vesting installments 6,000 options Three equal quarterly installments of 2,000 options each

Key Terms

exercise price, quarterly installments, effective date

3 terms

exercise price financial

"exercisable at $8.83 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

quarterly installments financial

"three equal quarterly installments of 2,000 options each"

effective date financial

"following the effective date of the merger"

The effective date is the specific calendar day when a contract, regulatory action, corporate change, or financial disclosure officially begins to apply and take legal or operational effect. For investors, it marks the moment rules, obligations, ownership, pricing, or reporting change—similar to the exact minute a light switch is flipped—so it determines when rights, liabilities, or market impacts start and which periods or transactions are affected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Kira Sheinerman’s NIKI option award?

Kira Sheinerman received 8,000 stock options on July 22, 2026, exercisable at $8.83 per share and expiring July 22, 2036. The options cover 8,000 shares of Niki BioSolutions common stock.

How do Kira Sheinerman’s NIKI options vest?

2,000 options vested immediately upon the merger closing. The remaining 6,000 vest in three equal quarterly installments of 2,000 options each, beginning on the first business day of the first full quarter following the merger’s effective date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 04:52 PM EDT Accepted by SEC EDGAR 10/21/2026 - 04:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sheinerman Kira

(Last) (First) (Middle)

116 VILLAGE BOULEVARD, SUITE 200

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$8.83	07/22/2026		A		8,000		(1)	07/22/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. The options vest as follows: (i) 2,000 options vested immediately upon the closing of the merger; and (ii) the remaining 6,000 options vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.

	/s/ Kira S. Sheinerman	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)